VenDex
1 abstract
Abstract
Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.Org: Alexandra Hospital - University of Athens, Medical School, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Würzburg University Hospital, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,